CRVS

Corvus Pharmaceuticals, Inc.

CRVS · CIK 1626971 · Annual (10-K) · Last 8 years

Financial Trends

Revenue
20162024
Net Income−$62M
20162024
Operating CF−$25M
20162024
Free Cash Flow−$25M
20162024

Income Statement

MetricFY 2024↕FY 2023↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕FY 2016↕
Revenue————————
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
SG&A Expense————————
Operating Income$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.1B$-0.0B
Net Income$-0.1B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-1.02$-0.56$-0.89—————
EPS (Diluted)$-1.02$-0.56$-0.89—————

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕FY 2016↕
Total Assets$0.1B$0.0B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B
Current Assets$0.1B$0.0B$0.0B$0.0B$0.1B$0.1B$0.1B$0.1B
Cash & Equivalents$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Total Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.0B$0.0B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕FY 2016↕
Operating Cash Flow$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B—
Investing Cash Flow$-0.0B$0.0B$-0.0B$0.0B$0.0B$-0.0B$0.1B—
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.0B$0.0B$0.1B$0.0B$0.0B$0.1B$0.0B—
← Companies